A biomarker model could be useful in predicting the possible progression of Alzheimer's disease among patients with mild cognitive impairment, according to a study from Italy published in Neurology. All patients with biomarkers saw their dementia symptoms progress, while only one patient in a group that lacked any of the model's biomarkers had symptom advancement during the study period.

Related Summaries